By Chris Wack Orphazyme A/S said it has begun to voluntarily delist its American depositary shares representing its ordinary shares from Nasdaq Global Select Market. The delisting is expected to...
12-Month Study of Arimoclomol Showed a Clinically Meaningful Treatment Effect, Corresponding to a Reduction in Disease Progression Highlights Arimoclomol is Under Regulatory Review in Europe...
OCALA, Fla., July 09, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has signed a contract to sponsor a Phase 2a Human Challenge Trial (HCT) to test...
By Matt Grossman Orphazyme AS is reducing its workforce by about two-thirds following a recent U.S. regulatory finding that more data was needed before its principal drug could be approved. The...
By Colin Kellaher Shares of Orphazyme A/S and CytRx Corp. plummeted on Friday after the U.S. Food and Drug Administration said it wouldn't approve a proposed drug for the fatal genetic...
By Colin Kellaher Shares of Orphazyme A/S dropped more than 60% Friday after the U.S. Food and Drug Administration rejected the biopharmaceutical company's application for approval of...
hVIVO to develop challenge agent based on new COVID-19 variants Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services contract research organisation (CRO) and world...
CytRx Corporation (OTCQB: CYTR) ("CytRx"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today noted that...
Call for volunteers to enroll in studies that will play a key part in developing effective vaccines and treatments for COVID-19 Open Orphan plc (AIM: ORPH), a rapidly growing specialist...
CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.